Incanthera PLC - oncology firm focused on skin cancer - Files two trademark names for the commercial use of its anti-skin cancer product Sol. Sol is the company's lead asset and is a topical formulation designed to treat solar keratosis and prevent the formation of skin cancers. The filings are in line with the ongoing commercialisation of the company's skin cancer technology formulation, Incanthera highlights.
"As our licencing discussions progress, the filing of these two trademark names will allow us to look at various branding and marketing opportunities in readiness for next steps," comments Chair Tim McCarthy.
"We continue to make good progress in discussions with our two prioritised partners."
Incanthera, which floated on AQSE in February last year, is using the funds from a GBP1 million placing in March to commercialise Sol.
Current stock price: 12.55 pence
Year-to-date change: down 30%
By Will Paige; willpaige@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.